Gregory Blaha is an Ophthalmology physician. OpenAlex indexes 18 publications with 227 citations (h-index 8); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
- Pilot Study: A Randomized Trial Of Anesthetic Agents For Intravitreal Injection
Sponsor: Lahey Clinic
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Alcon Vision LLCProgram year20251 payment
- Genentech, Inc.Program year20251 payment
- Beaver-Visitec International, Inc.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
89.7%Antineovascularisation agents79.9%Faricimab-svoa100%Part B, office-administered≥14 patientsCorticosteroid4.2%Prednisolone Acetate100%Part D≥110 patients+ 5 more classes in this area
Cancer & immunology
8.1%Vascular Endothelial Growth Factor Inhibitor8.1%Bevacizumab100%Part B, office-administered≥75 patientsMusculoskeletal
1.6%Cyclooxygenase Inhibitor1.6%Ketorolac Tromethamine100%Part D≥28 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Durability and Efficacy of Faricimab in Treatment‐Resistant Retinal Edema Utilizing “Real‐World” Dosing Regimens
Journal of Ophthalmology
2024 - Socioeconomic and Demographic Factors Contributing to COVID-19–Related Delays and Reductions in Primary Retinal Detachment Repair in a US Hot Spot
Journal of VitreoRetinal Diseases
2021 - Investigating the Arden hypothesis: a one-year trial investigating the prevention of dark adaptation as complementary therapy for diabetic macular edema
Investigative Ophthalmology & Visual Science
2021
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Emily Chew, MD
National Eye Institute
Robert Weinreb, MD
University of California San Diego
Harry Quigley, MD
Johns Hopkins University School of Medicine
Joel Schuman, MD
Wills Eye Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”